JP2005502595A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005502595A5 JP2005502595A5 JP2002587464A JP2002587464A JP2005502595A5 JP 2005502595 A5 JP2005502595 A5 JP 2005502595A5 JP 2002587464 A JP2002587464 A JP 2002587464A JP 2002587464 A JP2002587464 A JP 2002587464A JP 2005502595 A5 JP2005502595 A5 JP 2005502595A5
- Authority
- JP
- Japan
- Prior art keywords
- insulin
- derivative
- pharmaceutically acceptable
- acceptable salt
- produced therefrom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000001580 bacterial effect Effects 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 2
- 238000004108 freeze drying Methods 0.000 claims 2
- 210000003000 inclusion body Anatomy 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- 230000002194 synthesizing effect Effects 0.000 claims 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims 1
- -1 9-fluorenylmethoxycarbonyl Chemical group 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000002421 cell wall Anatomy 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 239000012043 crude product Substances 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000855 fermentation Methods 0.000 claims 1
- 230000004151 fermentation Effects 0.000 claims 1
- 239000012467 final product Substances 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
- 238000010532 solid phase synthesis reaction Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011128569A CN1162446C (zh) | 2001-05-10 | 2001-05-10 | 促胰岛素分泌肽衍生物 |
| PCT/CN2002/000316 WO2002090388A1 (en) | 2001-05-10 | 2002-05-08 | Derivatives of exendin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005502595A JP2005502595A (ja) | 2005-01-27 |
| JP2005502595A5 true JP2005502595A5 (https=) | 2006-01-05 |
| JP4287153B2 JP4287153B2 (ja) | 2009-07-01 |
Family
ID=4659603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002587464A Expired - Lifetime JP4287153B2 (ja) | 2001-05-10 | 2002-05-08 | インスリン指向性ペプチド誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7329646B2 (https=) |
| EP (2) | EP2223938B1 (https=) |
| JP (1) | JP4287153B2 (https=) |
| KR (1) | KR100902208B1 (https=) |
| CN (1) | CN1162446C (https=) |
| AU (1) | AU2002257497B2 (https=) |
| BR (1) | BRPI0209685B8 (https=) |
| CA (1) | CA2446394C (https=) |
| WO (1) | WO2002090388A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| CN1162446C (zh) * | 2001-05-10 | 2004-08-18 | 上海华谊生物技术有限公司 | 促胰岛素分泌肽衍生物 |
| CN100535003C (zh) * | 2004-09-06 | 2009-09-02 | 上海华谊生物技术有限公司 | Exendin 4的类似物 |
| US8030273B2 (en) | 2004-10-07 | 2011-10-04 | Novo Nordisk A/S | Protracted exendin-4 compounds |
| US7893017B2 (en) | 2004-10-07 | 2011-02-22 | Novo Nordisk A/S | Protracted GLP-1 compounds |
| CN100429227C (zh) * | 2005-06-29 | 2008-10-29 | 常州制药厂有限公司 | Exendin4多肽片段 |
| CN100374462C (zh) * | 2005-11-21 | 2008-03-12 | 大连帝恩生物工程有限公司 | 截短胰高血糖素样肽1(sGLP-1)、制法及其应用 |
| AU2007267833B2 (en) * | 2006-05-26 | 2012-07-26 | Amylin Pharmaceuticals, Llc | Composition and methods for treatment of congestive heart failure |
| CN101125207B (zh) | 2006-11-14 | 2012-09-05 | 上海华谊生物技术有限公司 | 带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途 |
| SI3456340T1 (sl) * | 2007-01-08 | 2022-08-31 | The Trustees Of The University Of Pennsylvania | Antagonisti receptorja za GLP-1 za uporabo pri zdravljenju prirojenega hiperinsulinizma |
| RU2413528C2 (ru) | 2007-01-18 | 2011-03-10 | Открытое Акционерное Общество "Валента Фармацевтика" | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения |
| CN101040936B (zh) * | 2007-04-28 | 2011-10-19 | 大连水产学院 | 防治鱼类寄生虫病的复方中草药制剂 |
| CN101215324B (zh) * | 2007-12-26 | 2010-11-24 | 吉林大学 | 艾塞那肽短肽模拟肽及其在制备糖尿病治疗药物中的应用 |
| KR100864584B1 (ko) * | 2008-02-25 | 2008-10-24 | 성균관대학교산학협력단 | 비오틴으로 수식된 엑센딘 유도체, 이의 제조방법 및 이의용도 |
| CN101463078B (zh) * | 2009-01-12 | 2011-07-27 | 华东师范大学 | 一种Exendin-4衍生物及其固相化学合成 |
| CN101665799A (zh) * | 2009-06-29 | 2010-03-10 | 华东师范大学 | 一种Exendin-4衍生物的重组制备方法和应用 |
| WO2011063549A1 (zh) * | 2009-11-26 | 2011-06-03 | Wu Xiaoyan | 长效exendin4的类似物 |
| CN102397558B (zh) | 2010-09-09 | 2013-08-14 | 中国人民解放军军事医学科学院毒物药物研究所 | Exendin-4类似物的定位聚乙二醇化修饰物及其用途 |
| CN102532301B (zh) * | 2010-12-31 | 2014-09-03 | 上海医药工业研究院 | 一类新型的Exendin-4类似物及其制备方法 |
| CN106928341B (zh) * | 2011-03-30 | 2021-06-01 | 上海仁会生物制药股份有限公司 | 定点单取代聚乙二醇化Exendin类似物及其制备方法 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| HK1211232A1 (en) | 2012-12-21 | 2016-05-20 | Sanofi | Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| WO2014147129A1 (en) | 2013-03-21 | 2014-09-25 | Sanofi-Aventis Deutschland Gmbh | Synthesis of cyclic imide containing peptide products |
| CN105189465B (zh) | 2013-03-21 | 2019-02-26 | 赛诺菲-安万特德国有限公司 | 合成含有乙内酰脲的肽产物 |
| EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AU2016267052B2 (en) | 2015-05-22 | 2022-01-20 | The Bot Of The Leland Stanford Junior University | Treatment of post-bariatric hypoglycemia with GLP-1 antagonists |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE164852T1 (de) | 1990-01-24 | 1998-04-15 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
| US5424286A (en) * | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| DK144093D0 (https=) * | 1993-12-23 | 1993-12-23 | Novo Nordisk As | |
| US6265204B1 (en) * | 1997-01-17 | 2001-07-24 | Genencor International, Inc. | DNA sequences, vectors, and fusion polypeptides for secretion of polypeptides in filamentous fungi |
| WO1999025727A2 (en) * | 1997-11-14 | 1999-05-27 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
| ATE383867T1 (de) * | 1997-11-14 | 2008-02-15 | Amylin Pharmaceuticals Inc | Neuartige exendin agonisten |
| US6514500B1 (en) | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
| CA2363712C (en) | 1999-05-17 | 2011-05-10 | Conjuchem Inc. | Long lasting insulinotropic peptides |
| US6506724B1 (en) | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
| US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
| EP1076066A1 (en) * | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| WO2001041561A1 (en) * | 1999-12-07 | 2001-06-14 | Lee Yong Hwa | A bathtub for a pet dog |
| CN1162446C (zh) * | 2001-05-10 | 2004-08-18 | 上海华谊生物技术有限公司 | 促胰岛素分泌肽衍生物 |
| CN1363654A (zh) | 2001-07-19 | 2002-08-14 | 上海华谊生物技术有限公司 | 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法 |
-
2001
- 2001-05-10 CN CNB011128569A patent/CN1162446C/zh not_active Expired - Lifetime
-
2002
- 2002-05-08 CA CA2446394A patent/CA2446394C/en not_active Expired - Lifetime
- 2002-05-08 BR BRPI0209685A patent/BRPI0209685B8/pt not_active IP Right Cessation
- 2002-05-08 EP EP10001237.6A patent/EP2223938B1/en not_active Expired - Lifetime
- 2002-05-08 JP JP2002587464A patent/JP4287153B2/ja not_active Expired - Lifetime
- 2002-05-08 AU AU2002257497A patent/AU2002257497B2/en not_active Expired
- 2002-05-08 WO PCT/CN2002/000316 patent/WO2002090388A1/zh not_active Ceased
- 2002-05-08 KR KR1020037014451A patent/KR100902208B1/ko not_active Expired - Lifetime
- 2002-05-08 EP EP02727167A patent/EP1386930A4/en not_active Withdrawn
-
2003
- 2003-11-07 US US10/704,409 patent/US7329646B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005502595A5 (https=) | ||
| US8188216B2 (en) | Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery | |
| US9963483B2 (en) | Process for producing self-assembling peptide derivatives | |
| JP3266311B2 (ja) | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 | |
| JP6050096B2 (ja) | 環状抗微生物ペプチド | |
| AU633872B2 (en) | Glycine derivatives | |
| DE60000665T3 (de) | Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen | |
| KR101904808B1 (ko) | 데가렐릭스 및 이의 중간 화합물의 제조 방법 | |
| JP2005502663A5 (https=) | ||
| JP2000256397A (ja) | 新規な環状テトラペプチド誘導体とその医薬用途 | |
| EP2660247A2 (en) | High penetration prodrug compositions of peptides and peptide-related compounds | |
| SK32693A3 (en) | Cyclopeptides, a method of preparing them and their use as drugs | |
| JP2004531242A5 (https=) | ||
| JPH11292840A (ja) | ノルスタチン誘導体又はその塩 | |
| Kurasaki et al. | Isostearyl mixed anhydrides for the preparation of N-Methylated peptides using C-terminally unprotected N-Methylamino acids | |
| EP0353565A1 (en) | Immunostimulating peptides, a process for their preparation and pharmaceutical commpositions containing them | |
| EP2235039A2 (en) | Methods of peptide modification | |
| CA1062250A (en) | Tripeptide derivatives with central nervous system activity and preparation thereof | |
| JPS60231697A (ja) | ペプチド | |
| JPH03502930A (ja) | Ｔ細胞のサプレツサー活性を有するペプチド | |
| JPS5951935B2 (ja) | 新規なペプチドおよびその製造法 | |
| Reid et al. | MIMICKING EXTENDED CONFORMATIONS OF PROTEASE SUBSTRATES: DESIGNING CYCLIC PEPTIDOMIMETICS TO INHIBIT | |
| JPH10330398A (ja) | 新規環状ペプチド | |
| CN1165521A (zh) | 苯基肽，该肽及含有所述肽的药物组合物的制备方法 | |
| JPH01197465A (ja) | 新規アルギニン誘導体、その製法及びペプチド合成における使用法 |